The primary efficacy endpoint was the change of the glycated hemoglobin level from baseline to the end of each trial in the patient receiving once-weekly insulin icodec vs. once-daily basal insulins, such as degludec, glargine U100, and glargine U300; the major safety endpoints were the rates of level 2 or level 3 hypoglycemia per patient-year of exposure (PYE) in the patient receiving once-weekly insulin icodec vs. once-daily basal insulins. This evidence concerns the gene INS and Hypoglycemia.